Hiroaki Takeoka

1.3k total citations
43 papers, 738 citations indexed

About

Hiroaki Takeoka is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Hiroaki Takeoka has authored 43 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 11 papers in Epidemiology. Recurrent topics in Hiroaki Takeoka's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Lung Cancer Research Studies (11 papers). Hiroaki Takeoka is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Lung Cancer Research Studies (11 papers). Hiroaki Takeoka collaborates with scholars based in Japan, United States and Germany. Hiroaki Takeoka's co-authors include Kazuhiro Toyoda, Norihiro Furusyo, Jun Hayashi, Eiichi Ogawa, Shinji Maeda, Yasunori Sawayama, Koji Yamazaki, Gouji Toyokawa, Masayuki Murata and Masao Ichiki and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Hiroaki Takeoka

40 papers receiving 717 citations

Peers

Hiroaki Takeoka
Shanyu Qin China
Phaik‐Leng Cheah Malaysia
H.-P. Fischer Germany
Olivier Romano France
Jong‐Da Lian Taiwan
Nadia Mokhtar Egypt
Andrea Beer Austria
Dimitra Bon Germany
R Brenard Belgium
Eugenia Panaitescu Romania
Shanyu Qin China
Hiroaki Takeoka
Citations per year, relative to Hiroaki Takeoka Hiroaki Takeoka (= 1×) peers Shanyu Qin

Countries citing papers authored by Hiroaki Takeoka

Since Specialization
Citations

This map shows the geographic impact of Hiroaki Takeoka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Takeoka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Takeoka more than expected).

Fields of papers citing papers by Hiroaki Takeoka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Takeoka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Takeoka. The network helps show where Hiroaki Takeoka may publish in the future.

Co-authorship network of co-authors of Hiroaki Takeoka

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Takeoka. A scholar is included among the top collaborators of Hiroaki Takeoka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Takeoka. Hiroaki Takeoka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tago, Masaki, Taiju Miyagami, Yudai Suzuki, et al.. (2025). Features of Undiagnosed Abdominal Pain and Diagnostic Status of Acute Hepatic Porphyria in Japan: A Retrospective Study. International Journal of Medical Sciences. 22(12). 3014–3021.
2.
Okamoto, Masaki, Kiminori Fujimoto, Toyoshi Yanagihara, et al.. (2024). Predictive factors of progression in mild fibrosing interstitial lung disease patients with gender-age-physiology score of 3 or less. Respiratory Investigation. 63(1). 109–117. 1 indexed citations
3.
Takeoka, Hiroaki, et al.. (2023). Predictive Factors for the Necessity of Hospitalization of Patients With Acute Alcohol Intoxication. Journal of Clinical Medicine Research. 15(3). 161–165. 1 indexed citations
4.
Takeoka, Hiroaki, et al.. (2023). Vibrio vulnificus sepsis after shrimp shelling in a patient with preexisting primary biliary cholangitis: a case report. Journal of Medical Case Reports. 17(1). 27–27. 1 indexed citations
5.
Tanaka, Tomohiro, Masaki Okamoto, Norikazu Matsuo, et al.. (2023). Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine. Medicina. 59(3). 541–541.
6.
Morise, Masahiro, Hiroshi Sakai, Terufumi Kato, et al.. (2022). O13-4 Efficacy and intracranial activity of tepotinib in Japanese patients with MET exon 14 skipping (METex14) NSCLC (VISION). Annals of Oncology. 33. S475–S475. 1 indexed citations
7.
Kanavati, Fahdi, Gouji Toyokawa, Seiya Momosaki, et al.. (2021). A deep learning model for the classification of indeterminate lung carcinoma in biopsy whole slide images. Scientific Reports. 11(1). 8110–8110. 39 indexed citations
8.
Takeoka, Hiroaki, Kazuhiko Yamada, Yoshiko Naito, et al.. (2018). Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients. Anticancer Research. 38(6). 3779–3784. 4 indexed citations
9.
Ichiki, Masao, Hiroshi Wataya, Kazuhiko Yamada, et al.. (2017). Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer. OncoTargets and Therapy. Volume 10. 5107–5113. 20 indexed citations
10.
Tokito, Takaaki, Hiroaki Takeoka, Norikazu Matsuo, et al.. (2017). Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexed. Investigational New Drugs. 35(5). 662–664. 2 indexed citations
11.
Yamada, Kazuhiko, Masao Ichiki, Kazuhisa Takahashi, et al.. (2016). A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 78(3). 501–507. 9 indexed citations
12.
Yamada, Kazuhiko, Hiroaki Takeoka, Yuji Mizoguchi, et al.. (2014). Feasibility Re-evaluation of 75 mg/m2 Docetaxel in Japanese Patients with Previously Treated Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology. 44(4). 338–345. 3 indexed citations
13.
Takeoka, Hiroaki, Kazuhiko Yamada, Koichi Azuma, et al.. (2014). Phase I Study of Carboplatin Combined with Pemetrexed for Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology. 44(5). 472–478. 4 indexed citations
14.
Azuma, Koichi, Tsukasa Yoshida, Kazuhiko Yamada, et al.. (2013). Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy. PLoS ONE. 8(8). e71356–e71356. 21 indexed citations
15.
Nabeshima, Shigeki, et al.. (2012). A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment of seasonal influenza. Journal of Infection and Chemotherapy. 18(4). 534–543. 67 indexed citations
16.
Yamada, Kazuhiko, Tsukasa Yoshida, Yoshio Zaizen, et al.. (2011). Clinical Practice in Management of Hydration for Lung Cancer Patients Receiving Cisplatin-based Chemotherapy in Japan: A Questionnaire Survey. Japanese Journal of Clinical Oncology. 41(11). 1308–1311. 12 indexed citations
17.
Toyoda, Kazuhiro, Norihiro Furusyo, Hiroaki Takeoka, et al.. (2008). Epidemiological study of hepatitis E virus infection in the general population of Okinawa, Kyushu, Japan. Journal of Gastroenterology and Hepatology. 23(12). 1885–1890. 24 indexed citations
18.
Furusyo, Norihiro, Yasunori Sawayama, Shinji Maeda, et al.. (2007). High molecular weight form of adiponectin levels of Japanese patients with chronic hepatitis C virus infection. Hepatology Research. 37(12). 1052–1061. 4 indexed citations
19.
Ogawa, Eiichi, Norihiro Furusyo, Kazuhiro Toyoda, et al.. (2007). Transient elastography for patients with chronic hepatitis B and C virus infection: Non‐invasive, quantitative assessment of liver fibrosis. Hepatology Research. 37(12). 1002–1010. 79 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shanyu Qin Breakdown of academic impact, for papers by Phaik‐Leng Cheah Breakdown of academic impact, for papers by H.-P. Fischer Breakdown of academic impact, for papers by Olivier Romano Breakdown of academic impact, for papers by Jong‐Da Lian Breakdown of academic impact, for papers by Nadia Mokhtar Breakdown of academic impact, for papers by Andrea Beer Breakdown of academic impact, for papers by Dimitra Bon Breakdown of academic impact, for papers by R Brenard Breakdown of academic impact, for papers by Eugenia Panaitescu
Rankless by CCL
2026